153 related articles for article (PubMed ID: 37844295)
21. Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor.
Zhang H; Bai L; Wu XQ; Tian X; Feng J; Wu X; Shi GH; Pei X; Lyu J; Yang G; Liu Y; Xu W; Anwaier A; Zhu Y; Cao DL; Xu F; Wang Y; Gan HL; Sun MH; Zhao JY; Qu Y; Ye D; Ding C
Nat Commun; 2023 Jul; 14(1):4274. PubMed ID: 37460463
[TBL] [Abstract][Full Text] [Related]
22. Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation.
Li F; Peng X; Zhou J; Chen Q; Chen Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3257-3266. PubMed ID: 35713705
[TBL] [Abstract][Full Text] [Related]
23. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
24. Biallelic
Maroto P; Anguera G; Roldan-Romero JM; Apellániz-Ruiz M; Algaba F; Boonman J; Nellist M; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C
J Natl Compr Canc Netw; 2018 Apr; 16(4):352-358. PubMed ID: 29632054
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
Bratslavsky G; Gleicher S; Jacob JM; Sanford TH; Shapiro O; Bourboulia D; Gay LM; Andrea Elvin J; Vergilio JA; Suh J; Ramkissoon S; Severson EA; Killian JK; Schrock AB; Chung JH; Miller VA; Mollapour M; Ross JS
Urol Oncol; 2021 Jun; 39(6):367.e1-367.e5. PubMed ID: 33775530
[TBL] [Abstract][Full Text] [Related]
26. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
28. BAP1-Mutated Clear Cell Renal Cell Carcinoma.
Gallan AJ; Parilla M; Segal J; Ritterhouse L; Antic T
Am J Clin Pathol; 2021 Apr; 155(5):718-728. PubMed ID: 33210135
[TBL] [Abstract][Full Text] [Related]
29. Collecting duct carcinoma with retroperitoneal mass as initial presentation: a rare case report.
Ye R; Liao Y; Xia T; Zhang X; Lu Q; Xiao X
BMC Urol; 2023 Jul; 23(1):127. PubMed ID: 37495956
[TBL] [Abstract][Full Text] [Related]
30. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
31. Rare renal cell carcinoma with haemangioblastoma-like features and leiomyomatous stroma: report of a unique case with TSC2 and SETD2 variations.
Kong J; Tao J; Wang Q; Zhang Q; Yin L
World J Surg Oncol; 2022 Dec; 20(1):395. PubMed ID: 36510186
[TBL] [Abstract][Full Text] [Related]
32. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
33. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
[TBL] [Abstract][Full Text] [Related]
34. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
[TBL] [Abstract][Full Text] [Related]
35. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.
Chen CV; Croom NA; Simko JP; Stohr BA; Chan E
Hum Pathol; 2022 Jan; 119():85-93. PubMed ID: 34800526
[TBL] [Abstract][Full Text] [Related]
36. METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression.
Liu Z; Sun T; Piao C; Zhang Z; Kong C
J Transl Med; 2021 May; 19(1):209. PubMed ID: 33985542
[TBL] [Abstract][Full Text] [Related]
37. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma.
Sorokina M; Stupichev D; Lyu Y; Ramachandran A; Miheecheva N; Brown JH; Nomie K; Postovalova E; Bagaev A; Tsiper M; Hsieh JJ
Clin Genitourin Cancer; 2021 Dec; 19(6):e374-e381. PubMed ID: 34389275
[TBL] [Abstract][Full Text] [Related]
39. Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin.
Wei EY; Chen YB; Hsieh JJ
BMJ Case Rep; 2015 Oct; 2015():. PubMed ID: 26494726
[TBL] [Abstract][Full Text] [Related]
40. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
